SFXN1 and neoplasm: Patients with SFXN1 high expression have relatively lower stromal score, immune score, and estimate score compared with the low expression group, which was consistent with the observation that patients with high SFXN1 expression had higher tumor purity (P < 0.001, Fig. 6A-D) and SFXN1 upregulation may increase malignancy in patients.